Specific inhibitors targeting the anti-fibrosis treatment
The inhibition of the interaction between the JMJD6 protein and collagen could represent a new approach aimed at preventing and treating fibrosis, and at counteracting the formation of tumor metastases. The invention concerns a monoclonal antibody, called P4E11, with inhibitory activity on JMJD6 capable of inhibiting its interaction with collagen, counteracting the formation of fibrosis.
The inhibition of the interaction between the JMJD6 protein and the collagen can represent a new approach to prevent and treat fibrosis, and to counteract the formation of tumor metastases. In preclinical breast cancer models, treatment with the P4E11 monoclonal antibody, which binds JMJD6 and prevents its interaction with collagen, reduced the number of lung metastases. Furthermore, treatment with P4E11 reduced the toxic and fibrotizing effects of bleomycin on the lung parenchyma.
- Treatment of diseases associated with fibrosis;
- Combination with chemotherapy drugs to improve its effectiveness and reduce its fibrotic activity;
- Anti-metastatic treatment of tumours.
- Better penetration of drugs;
- Administration of lower doses;
- Reduction of side effects;
- Greater therapeutic efficacy.